Shares of TG Therapeutics Inc (NASDAQ:TGTX) have been given an average rating of “Buy” by the nine analysts that are currently covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $16.80.
TGTX has been the topic of a number of research reports. HC Wainwright set a $5.00 price objective on SuperCom and gave the company a “buy” rating in a report on Friday, April 12th. Zacks Investment Research cut Zymeworks from a “buy” rating to a “hold” rating in a report on Saturday, April 6th. BidaskClub raised Winmark from a “sell” rating to a “hold” rating in a report on Tuesday, May 14th. B. Riley reissued a “buy” rating on shares of TG Therapeutics in a report on Tuesday, June 11th. Finally, Cantor Fitzgerald initiated coverage on CytomX Therapeutics in a report on Monday, May 13th. They set an “overweight” rating and a $21.00 price objective on the stock.
In related news, CFO Sean A. Power sold 17,654 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $8.47, for a total transaction of $149,529.38. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michael S. Weiss purchased 50,000 shares of TG Therapeutics stock in a transaction that occurred on Wednesday, June 26th. The shares were bought at an average price of $7.04 per share, for a total transaction of $352,000.00. The disclosure for this purchase can be found here. Company insiders own 14.20% of the company’s stock.
Shares of NASDAQ:TGTX traded up $0.04 on Friday, hitting $8.00. The company’s stock had a trading volume of 38,653 shares, compared to its average volume of 1,769,710. The firm’s 50-day moving average price is $7.50. TG Therapeutics has a 1 year low of $3.32 and a 1 year high of $13.60. The company has a quick ratio of 1.72, a current ratio of 1.72 and a debt-to-equity ratio of 1.89.
TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.01. The firm had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.04 million. TG Therapeutics had a negative return on equity of 309.17% and a negative net margin of 99,471.43%. On average, equities research analysts expect that TG Therapeutics will post -1.58 EPS for the current fiscal year.
About TG Therapeutics
TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.
Read More: Diluted Earnings Per Share
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.